By Maxx Chatsko Wall Street hasn’t fully digested what currency devaluation really means for biotech stocks. If the preliminary second-quarter 2022 earnings from 10x Genomics (TXG) – Get 10x Genomics Inc. Report are any guide, then investors are in for a decent amount of pain this earnings season. And a strong U.S. dollar is likely to be one of the primary culprits. The lab-hardware developer generated 53% of its revenue from the U.S. in 2021, but even that wasn’t enough to protect investors. 10x Genomics expects to report a 1% decline in Q2 revenue compared with the year-earlier period. An 11…